| Filed On | Filing |
|---|---|
| 10 Oct 2024 | SC 13D/A |
| 30 Sep 2024 | 15-12G |
| 20 Sep 2024 | 25-NSE |
| 17 Sep 2024 | 8-K: Entry into a Material Definitive Agreement |
| 09 Sep 2024 | S-8 POS |
| 09 Sep 2024 | S-8 POS |
| 09 Sep 2024 | S-8 POS |
| 09 Sep 2024 | S-8 POS |
| 09 Sep 2024 |
Form 4: Leonard Braden Michael, 10% owner
Bought 5,100 shares ($7.14K) · Bought 25,000 shares ($37.1K) |
| 06 Sep 2024 | 8-K: Entry into a Material Definitive Agreement |
| 05 Sep 2024 |
Form 4: Leonard Braden Michael, 10% owner
Bought 500 shares ($2K) |
| 05 Sep 2024 |
8-K/A: Entry into a Material Definitive Agreement
As previously disclosed in the periodic reports filed by Talis Biomedical Corporation (the “Company”) with the U.S. Securities and Exchange Commission (the “SEC”), the Company and certain of its current and former officers and directors ... |
| 04 Sep 2024 |
Form 4: Leonard Braden Michael, 10% owner
Bought 151 shares ($642) |
| 03 Sep 2024 | 8-K: Entry into a Material Definitive Agreement |
| 28 Aug 2024 |
Form 4: Leonard Braden Michael, 10% owner
Bought 13,167 shares ($51.3K) · Bought 1,215 shares ($4.81K) |
| 23 Aug 2024 | 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule |
| 19 Aug 2024 | 10-Q |
| 14 Aug 2024 | SC 13G/A |
| 14 Aug 2024 |
Form 3: Leonard Braden Michael, 10% owner
Holds 203,569 shares of Common Stock |
| 14 Aug 2024 | SC 13G |
Loading...
